PAR STERILE PRODUCTS, LLC – Trademark Portfolio
Entity Type: 03
PAR STERILE PRODUCTS, LLC holds 20 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 17 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 16 trademarks are registered. Notable registered marks include APLISOL, KETALAR, PITOCIN, BREVITAL, and DANTRIUM. The owner is based in WOODCLIFF LAKE, NJ.
300 TICE BLVD
WOODCLIFF LAKE, NJ 07677
Showing of trademarks Trademarks
Trademark Classifications
PAR STERILE PRODUCTS, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does PAR STERILE PRODUCTS, LLC have?
PAR STERILE PRODUCTS, LLC has 20 U.S. trademarks filed with the USPTO. Of these, 16 registered, 3 abandoned, 1 cancelled.
What trademark classes does PAR STERILE PRODUCTS, LLC file in?
PAR STERILE PRODUCTS, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are PAR STERILE PRODUCTS, LLC's most well-known trademarks?
PAR STERILE PRODUCTS, LLC's registered trademark portfolio includes well-known marks such as APLISOL, KETALAR, PITOCIN, BREVITAL, and DANTRIUM. These are among 16 currently registered trademarks in the portfolio.
What is PAR STERILE PRODUCTS, LLC's trademark registration success rate?
PAR STERILE PRODUCTS, LLC has a 80% trademark registration rate, with 16 out of 20 resolved applications resulting in successful registration. Currently, 0 applications are pending review.